Pacira BioSciences (PCRX) FY2024 results: revenue $701 million, up 3.9% on the year

Pacira BioSciences, Inc. (PCRX) reported revenue of $701 million for fiscal 2024, the year ended 31 December 2024, up 3.9% on the year before. Net income was -$100 million, and diluted earnings per share $-2.15. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2026.

Revenue

$701 million

+3.9% on the year

FY2017FY2024

Operating margin

-10.5%

13.0% a year earlier

FY2017FY2024

Net income

-$100 million

FY2017FY2024

Diluted EPS

-$2.15

FY2017FY2024

this yearthe year beforeHover a bar for its figure.

The year in brief

The four quarters: Q1 FY2024 · Q2 FY2024 · Q3 FY2024 · Q4 FY2024

Income statement (profit and loss)

$ million	FY2024	FY2023	FY2022	On the year
Revenue	701	675	667	+3.9%
Cost of revenue	170	185	199	-7.7%
Gross profit	531	490	468	+8.2%
Gross margin	75.7%	72.6%	70.1%
Research and development	81.6	76.3	84.8	+7.0%
Selling, general and administrative	294	269	255	+9.2%
Operating income	-73.4	87.7	60.0
Operating margin	-10.5%	13.0%	9.0%
Interest expense	16.6	20.3	40.0	-18.4%
Pre-tax income	-63.1	61.7	13.3
Income tax	36.5	19.7	-2.6	+84.6%
Effective tax rate	n/a	32.0%	-19.6%
Net income	-99.6	42.0	15.9
Net margin	-14.2%	6.2%	2.4%
Diluted EPS	-$2.15	$0.89	$0.34

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	FY2024	FY2023	FY2022	On the year
Operating cash flow	189	155	145	+22.5%
Capital expenditure	10.6	15.2	30.1	-29.8%
Free cash flow	179	139	115	+28.1%
Free cash flow margin	25.5%	20.7%	17.3%
Cash from investing	-83.3	77.5	-225
Cash from financing	17.4	-183	-402
Depreciation and amortisation	78.8	75.6	91.5	+4.2%
Share-based compensation	51.2	47.9	48.1	+6.8%
Buybacks	25.0	0.0	0.0
Diluted shares, weighted	46m	52m	47m	-11.0%
Shares outstanding at period end	46m	46m	46m	-0.5%

Balance sheet

$ million	FY2024	FY2023	FY2022	On the year
Shareholders' equity	778	870	775	-10.5%
Debt	585	522	689	+12.0%
Operating lease liabilities	44.6	54.8	64.8	-18.5%
Other liabilities	145	127	152	+14.3%
Total liabilities and equity	1,554	1,574	1,681	-1.3%
Fixed assets	167	174	184	-3.9%
Goodwill	0.0	163	163
Intangible assets	426	483	541	-11.9%
Investments	208	128	222	+62.8%
Cash and equivalents	277	153	104	+80.5%
Receivables	113	106	98.4	+7.3%
Inventory	125	104	96.1	+20.1%
Other assets	237	263	274	-9.8%
Total assets	1,554	1,574	1,681	-1.3%

10-K for the year ended 31 December 2024, filed 26 February 2026: the filing.